P12931

PTMD Annotation Information


※ Protein Information

Tag Content
UniProt Accession SRC_HUMAN; P12931;
Entrez ID 6714
GenBank Protein ID NM_005417.4; NM_198291.2; XM_011529013.2; XM_017028024.1; XM_017028025.1; XM_017028026.1; XM_017028027.1;
GenBank Nucleotide ID NP_005408.1; NP_938033.1; XP_011527315.1; XP_016883513.1; XP_016883514.1; XP_016883515.1; XP_016883516.1;
Protein Name Proto-oncogene tyrosine-protein kinase Src (EC 2.7.10.2) (Proto-oncogene c-Src) (pp60c-src) (p60-Src)
Gene Name SRC; SRC1
Organism Homo sapiens
NCBI Taxa ID 9606
Functional DescriptionNon-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors. Participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy betwe(view all)
Sequence
(Fasta)
MGSNKSKPKD ASQRRRSLEP AENVHGAGGG AFPASQTPSK PASADGHRGP SAAFAPAAAE 60
PKLFGGFNSS DTVTSPQRAG PLAGGVTTFV ALYDYESRTE TDLSFKKGER LQIVNNTEGD 120
WWLAHSLSTG QTGYIPSNYV APSDSIQAEE WYFGKITRRE SERLLLNAEN PRGTFLVRES 180
ETTKGAYCLS VSDFDNAKGL NVKHYKIRKL DSGGFYITSR TQFNSLQQLV AYYSKHADGL 240
CHRLTTVCPT SKPQTQGLAK DAWEIPRESL RLEVKLGQGC FGEVWMGTWN GTTRVAIKTL 300
KPGTMSPEAF LQEAQVMKKL RHEKLVQLYA VVSEEPIYIV TEYMSKGSLL DFLKGETGKY 360
LRLPQLVDMA AQIASGMAYV ERMNYVHRDL RAANILVGEN LVCKVADFGL ARLIEDNEYT 420
ARQGAKFPIK WTAPEAALYG RFTIKSDVWS FGILLTELTT KGRVPYPGMV NREVLDQVER 480
GYRMPCPPEC PESLHDLMCQ CWRKEPEERP TFEYLQAFLE DYFTSTEPQY QPGENL 537

※ PTM-Disease Association

NumPTMDiseaseCell TypeTypePTM SitePMID
1PhosphorylationCervical squamous cell cancerP23696930
[Reference]: Phosphorylated c-Src is a novel predictor for recurrence in cervical squamous cell cancer patients
2PhosphorylationBreast cancer/tumor/carcinomacell lineP23353055
[Reference]: Silencing TRPM7 with RNA interference resulted in a significant decrease in migration and invasion capability of MDA-MB-435 breast cancer cells, and phosphorylation levels of Src and MAPK but not AKT
3PhosphorylationCervical cancer/carcinomaP24058594
[Reference]: The overexpression of scaffolding protein NEDD9 promotes migration and invasion in cervical cancer via tyrosine phosphorylated FAK and SRC
4Tyrosine PhosphorylationBreast cancer/tumor/carcinomaUY21512753909
[Reference]: Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215.
5Tyrosine PhosphorylationSevere osteopetrosistumor tissuePY41623526378
[Reference]: The phosphorylation of cellular Rous sarcoma oncogene (c-Src) at Tyr-527 is significantly elevated whereas at Tyr-416 is decreased in Lrrk1-deficient osteoclasts
6Tyrosine PhosphorylationOvarian cancer/carcinomatumor tissueUY41623277333
[Reference]: As shown in Table 1, significant differences in c-Src and phospho-Src expression were observed between the groups; a significantly greater proportion of patients in the ovarian cancer group had positive c-Src and phospho-Src expression (P < 0.001)
7Tyrosine PhosphorylationProstate cancer/carcinoma/adenocarcinomacell lineUY41623145001
[Reference]: In addition, although the expected enhanced phosphorylation of Src at Tyr-416 (activation site) is present in the most aggressive prostate cancer cell lines, unexpectedly high phosphorylation levels at the Tyr-527 inhibitory site are observed as well.
8Tyrosine PhosphorylationOral squamous cell carcinomaDY41923707351
[Reference]: Decreased phosphorylation of Src, CTTN, and FAK also followed EGCG treatment
9Tyrosine PhosphorylationBarrett's neoplasiaDY41914608530
[Reference]: Our data indicate that expression levels of IGF1-R, c-Src, and Bcl-X(L) proteins are coordinately elevated in Barrett's-associated neoplasia.
10Tyrosine PhosphorylationAcute myeloid leukaemia/Acute myelogenous leukemiaPY41918056483
[Reference]: A critical role for Lyn in acute myeloid leukemia.
11Tyrosine PhosphorylationGlioblastomaPY41922323579
[Reference]: Finally, phosphorylated Dock180(Y722) is coexpressed with EGFRvIII and phosphorylated Src(Y418) in clinical specimens, and such coexpression correlates with an extremely poor survival in glioblastoma patients.
12Tyrosine PhosphorylationHepatocellular carcinoma/Hepatocarcinoma/Hepatomatumor tissuePY41924296779; 23524339
[Reference]: PKC mediates fluctuant ERK-paxillin signaling for hepatocyte growth factor-induced migration of hepatoma cell HepG2
13Tyrosine PhosphorylationGestational choriocarcinomaJEG-3 cell linePY41923671128
[Reference]: Transfection of ASPP2 but not ASPP1, another tumor-suppressive ASPP, was found to be related to subsequent decreased Src-pY416 phosphorylation, suggesting an inactivating effect of ASPP2 on Src
14Tyrosine PhosphorylationGlioma/Adult gliomasUY41924358106
[Reference]: Evidence for post-translational processing of vascular endothelial (VE)-cadherin in brain tumors: towards a candidate biomarker.
15Tyrosine PhosphorylationProstate cancer/carcinoma/adenocarcinomaUY41917045208
[Reference]: Phosphorylated Src and AR higher in hormone-refractory prostate cancers than hormone-sensitive ones.
16Tyrosine PhosphorylationBreast cancer/tumor/carcinomaUY41921490376; 24358106; 12753909; 17967179; 26923594
[Reference]: the activated form of Src (phosphoY418) was highly detectable in brain tumor extracts, while it was barely detectable in non-tumor brain;HER2(+) breast cancer. Strong pY216, modest pY419.;in selected cell lines;higher in basal subtype BC;TNBC;higher in basal subtype BC;TNBC
17Tyrosine PhosphorylationColon cancer/carcinomaUY41917148760
[Reference]: We have validated the use of phospho-specific antibodies against Src Tyr(419) and paxillin Tyr(118) as biomarkers of dasatinib activity in vivo. Colon carcinoma-bearing mice treated with dasatinib showed a decrease in both phospho-Src Tyr(419) and phospho-paxillin Tyr(118) in peripheral blood mononuclear cells, which correlated with inhibition of Src activity in the colon tumors.?
18Tyrosine PhosphorylationSevere osteopetrosistumor tissuePY52723526378
[Reference]: The phosphorylation of cellular Rous sarcoma oncogene (c-Src) at Tyr-527 is significantly elevated whereas at Tyr-416 is decreased in Lrrk1-deficient osteoclasts
19Tyrosine PhosphorylationHepatocellular carcinoma/Hepatocarcinoma/HepatomaDY53024296779
[Reference]: Moreover, we also found that the phosphorylation level of negative regulatory site of Src (Y527) was significantly decreased in MPZL1-overexpressing cells
20Tyrosine PhosphorylationBarrett's neoplasiaDY53014608530
[Reference]: Our data indicate that expression levels of IGF1-R, c-Src, and Bcl-X(L) proteins are coordinately elevated in Barrett's-associated neoplasia.
21Tyrosine PhosphorylationColon cancer/carcinomaDY53023467908
[Reference]: Y530 phosphorylation in the carcinomas was greatly reduced as compared to FHC
22Tyrosine PhosphorylationBreast cancer/tumor/carcinomatumor tissueUY53021490376
[Reference]: High expression of Y416Src was significantly associated with metastatic disease (p=0.0327), whereas high expression of Y527Src was significantly associated with metastatic disease (p=0.0004), clinical stage (p=0.0062), as well as HER2 status (p=0.0149). High expression of either Y416Src or Y527Src was significantly correlated with poor overall survival (p=0.0049 and p<0.0001, respectively).
23Tyrosine PhosphorylationProstate cancer/carcinoma/adenocarcinomacell lineUY53023145001
[Reference]: In addition, although the expected enhanced phosphorylation of Src at Tyr-416 (activation site) is present in the most aggressive prostate cancer cell lines, unexpectedly high phosphorylation levels at the Tyr-527 inhibitory site are observed as well.

※ Disease Cross-ref Annotation

DatabaseAnnotation
Cancer Gene Census
colorectal cancer, endometrial carcinoma
CTD (Curated)
(count: 10)
(view all)
MESH:D001943 ; Breast Neoplasms
MESH:D006332 ; Cardiomegaly
MESH:D003092 ; Colitis
MESH:D003110 ; Colonic Neoplasms
MESH:D015179 ; Colorectal Neoplasms
MESH:D009361 ; Neoplasm Invasiveness
GWASdb
(count: 2)
rs747182; Lymphocyte counts; asthma|leukemia|lymphoma|lymphopenia|cardiovascular system disease
rs6018199; HIV-1 progression to AIDS and death; Human immunodeficiency virus infectious disease

※ PTM Sites

PTM Modification Sites
Phosphorylation
(count: 35)
(view all)
104       SRTETDLSFKKGERL     dbPAF
12        KSKPKDASQRRRSLE     dbPAF
17        DASQRRRSLEPAENV     dbPAF
182       FLVRESETTKGAYCL     dbPAF
183       LVRESETTKGAYCLS     dbPAF
187       SETTKGAYCLSVSDF     dbPAF
Acetylation
(count: 1)
203       NAKGLNVKHYKIRKL     PLMD

※ Protein-Protein Interaction

NetworkInteraction
ABSource
A7KAX9P12931HPRD
B4DLN2P12931HPRD
B7Z2A4P12931HPRD
E7ESA6P12931HPRD; IntAct; MINT
E9PB44P12931HPRD
E9PDT7P12931HPRD
F5H721P12931HPRD
G3V0F8P12931HPRD
H0Y8I4P12931MINT
O00254P12931IntAct; MINT
O00560P12931DIP
O08715P12931MINT
O14490P12931IntAct
O14746P12931HPRD
O14920P12931HPRD; IntAct
O15111P12931HPRD; IntAct
O15357P12931HPRD
O15360P12931IntAct
O15371P12931IntAct
O15455P12931MINT
O15492P12931HPRD
O15530P12931HPRD
O43150P12931IntAct; MINT
O43184P12931HPRD
O43281P12931IntAct; MINT
O43900P12931IntAct; MINT
O43909P12931IntAct
O43918P12931IntAct
O60493P12931IntAct
O60496P12931HPRD
O60500P12931HPRD
O60674P12931IntAct
O60716P12931HPRD
O75167P12931IntAct
O75469P12931HPRD
O75553P12931HPRD
O94887P12931HPRD
O95157P12931IntAct; MINT
O95297P12931HPRD
O95886P12931IntAct
P00519P12931IntAct; MINT;HPRD
P00533P12931HPRD; IntAct
P01112P12931HPRD; MINT
P01889P12931HPRD
P02686P12931MINT
P03372P12931HPRD; DIP; MINT;IntAct
P03891P12931HPRD
P04049P12931HPRD; MINT
P04083P12931HPRD
P04439P12931HPRD
P04626P12931HPRD; IntAct
P05023P12931IntAct
P05106P12931HPRD;MINT
P06213P12931HPRD
P06241P12931MINT
P06401P12931HPRD
P07355P12931HPRD
P07550P12931HPRD; MINT
P07900P12931HPRD; DIP
P07949P12931HPRD
P08034P12931HPRD
P08047P12931IntAct
P08069P12931HPRD
P08581P12931IntAct;HPRD
P08887P12931HPRD
P09327P12931HPRD
P09619P12931HPRD
P09769P12931HPRD
P09848P12931MINT
P0CG48P12931MINT
P10275P12931HPRD
P10301P12931IntAct; MINT
P10636P12931MINT
P10721P12931HPRD
P10827P12931HPRD
P11274P12931HPRD
P11831P12931HPRD
P12814P12931IntAct; MINT;HPRD
P12830P12931IntAct
P12931P12931HPRD; MINT
P12931P13645MINT
P12931P13688HPRD
P12931P13945HPRD; MINT
P12931P13987HPRD
P12931P14136HPRD
P12931P14921HPRD
P12931P14923HPRD
P12931P15036HPRD
P12931P15529HPRD
P12931P15586IntAct
P12931P15941HPRD; IntAct
P12931P16284HPRD; IntAct
P12931P16671HPRD
P12931P17252HPRD
P12931P17302HPRD
P12931P17600HPRD
P12931P17612HPRD
P12931P17706HPRD
P12931P18031HPRD; MINT
P12931P18206HPRD
P12931P18433MINT
P12931P18545HPRD; MINT
P12931P19174HPRD
P12931P19793HPRD
P12931P20138HPRD
P12931P20248DIP
P12931P20774IntAct
P12931P20810IntAct
P12931P20823HPRD
P12931P20936HPRD
P12931P21333IntAct
P12931P21860MINT
P12931P21980DIP
P12931P22460HPRD
P12931P22681HPRD; MINT
P12931P23469HPRD; MINT
P12931P23634HPRD
P12931P23743HPRD
P12931P23759IntAct
P12931P23760IntAct
P12931P24385DIP
P12931P24723HPRD
P12931P25092HPRD
P12931P25098HPRD
P12931P25101DIP
P12931P25445DIP; IntAct
P12931P25963HPRD
P12931P26373IntAct; MINT
P12931P27635MINT
P12931P27986HPRD; MINT
P12931P28340IntAct; MINT
P12931P29323HPRD
P12931P29353MINT;HPRD
P12931P30419HPRD
P12931P30530HPRD
P12931P31273IntAct
P12931P31749HPRD
P12931P31946HPRD
P12931P31994IntAct; MINT
P12931P31995IntAct; MINT
P12931P32121DIP
P12931P33151HPRD
P12931P35222HPRD; MINT
P12931P35228HPRD
P12931P35326MINT
P12931P35968HPRD; IntAct
P12931P36575HPRD
P12931P40198HPRD
P12931P40763HPRD; IntAct
P12931P41231HPRD
P12931P41240HPRD; IntAct
P12931P41743HPRD
P12931P42224HPRD
P12931P42226HPRD
P12931P42229HPRD
P12931P42679HPRD
P12931P42681HPRD
P12931P42684IntAct; MINT
P12931P42768HPRD
P12931P43405HPRD
P12931P43699IntAct
P12931P46013IntAct; MINT
P12931P46527HPRD; IntAct
P12931P47928IntAct; MINT
P12931P48023HPRD; IntAct
P12931P48960IntAct; MINT
P12931P49023HPRD
P12931P49407DIP
P12931P49789HPRD
P12931P49916IntAct
P12931P50570HPRD; MINT
P12931P50607HPRD
P12931P51636HPRD
P12931P51692HPRD
P12931P51813HPRD
P12931P52799HPRD; MINT
P12931P55196MINT
P12931P55774MINT
P12931P56945HPRD; IntAct; MINT
P12931P61978MINT;HPRD
P12931P61981HPRD
P12931P62258HPRD
P12931P62993HPRD
P12931P63244HPRD
P12931P67775MINT
P12931P68133MINT
P12931P68400IntAct
P12931P78329IntAct
P12931P78345IntAct
P12931P78347HPRD
P12931P78352HPRD
P12931P78357HPRD
P12931P98082HPRD
P12931P98161HPRD
P12931P98172HPRD
P12931Q00535HPRD
P12931Q02156HPRD
P12931Q03135HPRD; MINT
P12931Q03181HPRD
P12931Q04912HPRD
P12931Q04917HPRD
P12931Q05193HPRD; MINT
P12931Q05513HPRD
P12931Q05655HPRD; MINT
P12931Q05996IntAct; MINT
P12931Q06124MINT;HPRD
P12931Q06418HPRD
P12931Q07666HPRD; IntAct; MINT;MINT
P12931Q07889IntAct; MINT
P12931Q07890IntAct; MINT
P12931Q07954HPRD; MINT
P12931Q07960HPRD
P12931Q12778HPRD
P12931Q12824HPRD
P12931Q12879HPRD
P12931Q12913MINT
P12931Q12929HPRD
P12931Q13009HPRD
P12931Q13023IntAct; MINT
P12931Q13077HPRD
P12931Q13087IntAct
P12931Q13094MINT
P12931Q13114HPRD
P12931Q13177HPRD; MINT
P12931Q13191MINT
P12931Q13224HPRD
P12931Q13322HPRD
P12931Q13444HPRD; MINT
P12931Q13574HPRD
P12931Q13639MINT
P12931Q13796IntAct
P12931Q13813HPRD
P12931Q13905IntAct; MINT
P12931Q14008IntAct
P12931Q14118HPRD; IntAct; MINT
P12931Q14185IntAct; MINT
P12931Q14194MINT
P12931Q14247HPRD
P12931Q14289HPRD
P12931Q14721HPRD
P12931Q15027IntAct
P12931Q15036IntAct; MINT
P12931Q15139HPRD
P12931Q15257HPRD
P12931Q15464HPRD
P12931Q15642HPRD
P12931Q15654HPRD
P12931Q15746HPRD
P12931Q16825HPRD; MINT
P12931Q16832HPRD; MINT
P12931Q4V348MINT
P12931Q5TCZ1HPRD
P12931Q68CZ2IntAct
P12931Q68EM7HPRD
P12931Q6PIZ9HPRD
P12931Q6UB99HPRD
P12931Q75N03IntAct
P12931Q7Z7K6MINT
P12931Q85737MINT
P12931Q86WV1HPRD
P12931Q86X10IntAct
P12931Q86YH6MINT
P12931Q8IWT3IntAct
P12931Q8IZD9IntAct; MINT
P12931Q8IZL8HPRD
P12931Q8IZP0MINT
P12931Q8N4X5HPRD
P12931Q8N556MINT
P12931Q8N5H7HPRD
P12931Q8TB24IntAct; MINT
P12931Q8TBB1MINT
P12931Q8TD08HPRD
P12931Q8TEW6HPRD
P12931Q8WU20HPRD
P12931Q8WUM4HPRD; MINT
P12931Q8WX93MINT
P12931Q92731HPRD
P12931Q92845HPRD
P12931Q92918IntAct; MINT
P12931Q92988IntAct
P12931Q969G3HPRD
P12931Q96MU7HPRD
P12931Q96NS5IntAct
P12931Q96Q35IntAct
P12931Q99704HPRD
P12931Q99952HPRD
P12931Q9BWW9IntAct; MINT
P12931Q9BYB0IntAct; MINT
P12931Q9C0H9IntAct; MINT;MINT
P12931Q9H1R2IntAct; MINT
P12931Q9H204HPRD; IntAct; MINT
P12931Q9H5V8HPRD; MINT
P12931Q9H9L3IntAct
P12931Q9HBA0HPRD
P12931Q9HCU4IntAct; MINT
P12931Q9HDB9MINT
P12931Q9NQ76IntAct
P12931Q9NQC3IntAct; MINT
P12931Q9NQI0MINT
P12931Q9NR82HPRD
P12931Q9NRJ4IntAct
P12931Q9NRY4HPRD
P12931Q9NZA1MINT
P12931Q9NZC7HPRD
P12931Q9NZM4IntAct
P12931Q9NZV5IntAct
P12931Q9P1A6IntAct
P12931Q9UBY0HPRD
P12931Q9UGK3HPRD
P12931Q9UI08HPRD
P12931Q9UL51IntAct
P12931Q9ULH1HPRD; IntAct; MINT
P12931Q9ULV8HPRD
P12931Q9UN19HPRD
P12931Q9UPX8IntAct; MINT
P12931Q9UQC2HPRD
P12931Q9WNA9MINT
P12931Q9Y210HPRD
P12931Q9Y261MINT
P12931Q9Y2D5IntAct;MINT
P12931Q9Y2H0IntAct
P12931Q9Y2J2IntAct
P12931Q9Y2X7HPRD
P12931Q9Y3L3HPRD
P12931Q9Y4D1MINT
P12931Q9Y4K3HPRD
P12931Q9Y5K6HPRD
P12931Q9Y6K9HPRD; IntAct
P12931Q9Y6Q6HPRD